Integrated Filing — IndAS



General information about company
Scrip Code 532482
NSE Symbol GRANULES
MSEI Symbol NOTLISTED
ISIN INE101D01020
Name of company GRANULES INDIA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 28-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 07-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 28-May-2025   11:00:00
End date and time of board meeting 28-May-2025   13:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-01-24
Indicate Company website link for updated RPT policy of the Company https://granulesindia.com/wp-content/uploads/2025/02/Granules-Related-Party-Transactions-Policy-Updated-24.01.2025.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No default



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 7680260000 30301630000
Other income 304850000 406800000
Total income 7985110000 30708430000
2 Expenses
(a) Cost of materials consumed 3423050000 13738970000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 13240000 -297980000
(d) Employee benefit expense 965200000 3823440000
(e) Finance costs 134870000 627800000
(f) Depreciation, depletion and amortisation expense 379730000 1462300000
(f) Other Expenses
1 Other Expenses 2109620000 7389160000
Total other expenses 2109620000 7389160000
Total expenses 7025710000 26743690000
3 Total profit before exceptional items and tax 959400000 3964740000
4 Exceptional items 307500000 307500000
5 Total profit before tax 1266900000 4272240000
6 Tax expense
7 Current tax 388180000 1098790000
8 Deferred tax -61820000 -19910000
9 Total tax expenses 326360000 1078880000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 940540000 3193360000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 940540000 3193360000
17 Other comprehensive income net of taxes 135780000 40850000
18 Total Comprehensive Income for the period 1076320000 3234210000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 242540000 242540000
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 33787560000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.88 13.17
Diluted earnings (loss) per share from continuing operations 3.88 13.17
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.88 13.17
Diluted earnings (loss) per share from continuing and discontinued operations 3.88 13.17
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 13602550000
Capital work-in-progress 1202470000
Investment property 0
Goodwill 0
Other intangible assets 447460000
Intangible assets under development 5380000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 12815300000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 173200000
Total non-current financial assets 12988500000
Deferred tax assets (net) 0
Other non-current assets 403230000
Total non-current assets 28649590000
2 Current assets
Inventories 6484850000
Current financial asset
Current investments 0
Trade receivables, current 12945280000
Cash and cash equivalents 1523400000
Bank balance other than cash and cash equivalents 179960000
Loans, current 0
Other current financial assets 42860000
Total current financial assets 14691500000
Current tax assets (net) 0
Other current assets 1692790000
Total current assets 22869140000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 51518730000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 242540000
Other equity 33787560000
Total equity attributable to owners of parent 34030100000
Non controlling interest
Total equity 34030100000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 864940000
Total non-current financial liabilities 864940000
Provisions, non-current 315030000
Deferred tax liabilities (net) 304290000
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 1484260000
Current liabilities
Current financial liabilities
Borrowings, current 8081930000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 60310000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 6071290000
Total Trade payable 6131600000
Other current financial liabilities 1239250000
Total current financial liabilities 15452780000
Other current liabilities 122860000
Provisions, current 309310000
Current tax liabilities (Net) 119420000
Deferred government grants, Current 0
Total current liabilities 16004370000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 17488630000
Total equity and liabilites 51518730000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items will not be reclassified to profit and loss 20920000 20920000
Total Amount of items that will not be reclassified to profit and loss 20920000 20920000
2 Income tax relating to items that will not be reclassified to profit or loss 5270000 5270000
3 Amount of items that will be reclassified to profit and loss
1 Items will be reclassified to profit and loss 160530000 33670000
Total Amount of items that will be reclassified to profit and loss 160530000 33670000
4 Income tax relating to items that will be reclassified to profit or loss 40400000 8470000
5 Total Other comprehensive income 135780000 40850000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 4272240000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 627800000
Adjustments for decrease (increase) in inventories -698700000
Adjustments for decrease (increase) in trade receivables, current 3215250000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 144300000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current -90640000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 1462300000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 40740000
Adjustments for dividend income 0
Adjustments for interest income 21170000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 183230000
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 4863110000
Net cash flows from (used in) operations 9135350000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 908290000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 8227060000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 3401340000
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 2108950000
Proceeds from sales of investment property 62150000
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 21060000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -97250000
Net cash flows from (used in) investing activities -5524330000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 49980000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 20985790000
Repayments of borrowings 23407840000
Payments of lease liabilities 91450000
Dividends paid 363550000
Interest paid 571180000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -3398250000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -695520000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents -11870000
Net increase (decrease) in cash and cash equivalents -707390000
Cash and cash equivalents cash flow statement at beginning of period 2230790000
Cash and cash equivalents cash flow statement at end of period 1523400000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 S.R. BATLIBOI & ASSOCIATES LLP Yes 31-Jul-2027


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Granules India Limited Granules USA Inc Subsidiary Sale of goods or services 3500000000 Approved 1155830000 0 0
2 Granules India Limited Granules Pharmaceuticals Inc Subsidiary Sale of goods or services 11000000000 Approved 4879920000 0 0
3 Granules India Limited Granules Consumer Health Inc Step down subsidiary Sale of goods or services 5500000000 Approved 1672090000 0 0
4 Granules India Limited Granules Life Sciences Pvt Ltd Subsidiary Sale of goods or services 1000000000 Approved 190680000 0 0
5 Granules India Limited Granules Pharmaceuticals Inc Subsidiary Any other transaction Reimbursement of Expenses Approved 53000000 0 0
6 Granules India Limited Granules USA Inc Subsidiary Any other transaction Reimbursement of Expenses Approved 30930000 0 0
7 Granules India Limited Granules Consumer Health Inc Step down subsidiary Any other transaction Reimbursement of Expenses Approved 13510000 0 0
8 Granules India Limited Granules Life Sciences Pvt Ltd Subsidiary Any other transaction Reimbursement from Expenses Approved 104130000 0 0
9 Granules India Limited Granules Peptides Pvt Ltd Subsidiary Any other transaction Reimbursement from Expenses Approved 26560000 0 0
10 Granules India Limited Product Armor Packaging Pvt Ltd Enterprises over which key management personnel or their relatives exercise significant influence Purchase of goods or services 800000000 Approved 166700000 0 0
11 Granules India Limited Granules Pharmaceuticals Inc Subsidiary Purchase of goods or services 1000000000 Approved 177170000 0 0
12 Granules India Limited Granules CZRO Pvt Ltd Subsidiary Any other transaction Reimbursement from Expenses Approved 0 0 0
13 Granules India Limited Granules USA Inc Subsidiary Any other transaction Commission on Corporate Guarantee Approved 2690000 0 0
14 Granules India Limited Granules USA Inc Subsidiary Any other transaction Cross Charge Approved 6830000 0 0
15 Granules India Limited Granules Pharmaceuticals Inc Subsidiary Any other transaction Cross Charge Approved 15960000 0 0
16 Granules India Limited Granules Life Sciences Pvt Ltd Subsidiary Any other transaction Cross Charge Approved 1470000 0 0
17 Granules India Limited Granules USA Inc Subsidiary Any other transaction Sales commission accrued 300000000 Approved 43350000 0 0
18 Granules India Limited Granules CZRO Pvt Ltd Subsidiary Any other transaction Sale of Assets Approved 20000 0 0
19 Granules India Limited Granules Life Sciences Pvt Ltd Subsidiary Investment 1250000000 Approved 800000000 0 0
20 Granules India Limited Granules CZRO Pvt Ltd Subsidiary Investment 751540000 Approved 150000000 0 0
21 Granules India Limited Granules Peptides Pvt Ltd Subsidiary Investment 4000000000 Approved 2000000000 0 0
22 Granules India Limited Granules Trust Enterprises over which key management personnel or their relatives exercise significant influence Any other transaction Contribution towards CSR Approved 77300000 0 0
23 Granules India Limited Granules CZRO Pvt Ltd Subsidiary Purchase of goods or services Approved 100000 0 0
24 Granules India Limited Chigurupati family trust Enterprises over which key management personnel or their relatives exercise significant influence Any other transaction Rent Deposit Approved 30670000 0 0
25 Granules India Limited Chigurupati family trust Enterprises over which key management personnel or their relatives exercise significant influence Any other transaction Rent Accrued Approved 20440000 0 0
26 Granules India Limited Dr. Krishna Prasad Chigurupati Key Management Personnel Any other transaction Managerial Remuneration Approved 134920000 0 0
27 Granules India Limited Mrs. Uma Devi Chigurupati Key Management Personnel Any other transaction Managerial Remuneration Approved 13490000 0 0
28 Granules India Limited Mr. Harsha Chigurupati Key Management Personnel Any other transaction Managerial Remuneration Approved 13490000 0 0
29 Granules India Limited Mrs. Priyanka Chigurupati Key Management Personnel Any other transaction Managerial Remuneration Approved 13490000 0 0
30 Granules India Limited Dr. K.V.S. Ram Rao Key Management Personnel Any other transaction Managerial Remuneration Approved 51710000 0 0
31 Granules India Limited Non Executive Directors Non Executive Director Any other transaction Sitting fees and Commission Approved 11560000 0 0
32 Granules India Limited Key Management Personnel Key Management Personnel Any other transaction Salary Approved 12610000 0 0
33 Granules India Limited Granules USA Inc Subsidiary Any other transaction Trade Receivable Approved 0 1351610000 1387350000
34 Granules India Limited Granules Pharmaceuticals Inc Subsidiary Any other transaction Trade Receivable Approved 0 2919100000 4967920000
35 Granules India Limited Granules Consumer Health Inc Step down subsidiary Any other transaction Trade Receivable Approved 0 3020330000 1345700000
36 Granules India Limited Granules Life Sciences Pvt Ltd Subsidiary Any other transaction Trade Receivable Approved 0 37680000 182280000
37 Granules India Limited Granules USA Inc Subsidiary Any other transaction Trade Payable Approved 0 32090000 0
38 Granules India Limited Granules Pharmaceuticals Inc Subsidiary Any other transaction Trade Payable Approved 0 103200000 190920000
39 Granules India Limited Product Armor Packaging Pvt Ltd Enterprises over which key management personnel or their relatives exercise significant influence Any other transaction Trade Payable Approved 0 1340000 3350000
40 Granules India Limited Granules CZRO Pvt Ltd Subsidiary Any other transaction Trade Payable Approved 0 0 120000
41 Granules India Limited Granules USA Inc Subsidiary Any other transaction Other Payable Approved 0 35150000 44960000
42 Granules India Limited Granules Pharmaceuticals Inc Subsidiary Any other transaction Other Payable Approved 0 100000 2490000
43 Granules India Limited Granules Life Sciences Pvt Ltd Subsidiary Any other transaction Other Receivable Approved 0 1450000 1590000
44 Granules India Limited Granules CZRO Pvt Ltd Subsidiary Any other transaction Other Receivable Approved 0 1370000 1380000
45 Granules India Limited Granules USA Inc Subsidiary Any other transaction Other Receivable Approved 0 5270000 17400000
46 Granules India Limited Granules Pharmaceuticals Inc Subsidiary Any other transaction Other Receivable Approved 0 10610000 26760000
47 Granules India Limited Granules Europe Ltd Subsidiary Loan Approved 0 0 0
48 Granules India Limited Granules USA Inc Subsidiary Investment Approved 0 11630000 11630000
49 Granules India Limited Granules Pharmaceuticals Inc Subsidiary Investment Approved 0 5645370000 5645370000
50 Granules India Limited Granules Life Sciences Pvt Ltd Subsidiary Investment Approved 0 2500000000 3300000000
51 Granules India Limited Granules CZRO Pvt Ltd Subsidiary Investment Approved 0 1700000000 1850000000
52 Granules India Limited Granules Europe Ltd Subsidiary Investment Approved 0 10000 0
53 Granules India Limited Granules USA Inc Subsidiary Any other transaction Sales Commission Payable Approved 0 50760000 78030000
54 Granules India Limited Granules USA Inc Subsidiary Any other transaction Corporate Guarantee Approved 0 1256450000 1281870000
55 Granules India Limited Granules Life Sciences Pvt Ltd Subsidiary Any other transaction Corporate Guarantee Approved 0 1567620000 0
56 Granules India Limited Granules Consumer Health Inc Step down subsidiary Any other transaction Other Payable Approved 0 10620000 15870000
57 Granules India Limited Granules Life Sciences Pvt Ltd Subsidiary Any other transaction Other Payable Approved 0 0 104130000
58 Granules India Limited Granules Peptides Pvt Ltd Subsidiary Investment Approved 0 0 2000000000
59 Granules India Limited Chigurupati family trust Enterprises over which key management personnel or their relatives exercise significant influence Any other transaction Rent Deposit Approved 0 0 30670000
60 Granules India Limited Granules Life Sciences Pvt Ltd Subsidiary Any other transaction Sale of Assets Approved 48120000 0 0
61 Granules India Limited Granules Pharmaceuticals Inc Subsidiary Any other transaction Technical Know-how, manufacturing support and R & D services Approved 369630000 0 0
62 Granules India Limited Granules Pharmaceuticals Inc Subsidiary Any other transaction Management and administrative support activity Approved 277220000 0 0
63 Granules India Limited Granules Peptides Pvt Ltd Subsidiary Any other transaction Other Receivable Approved 0 0 26560000
64 Granules Consumer Health Inc Granules Pharmaceuticals Inc Step down subsidiary Sale of goods or services Approved 263430000 0 0
65 Granules Consumer Health Inc Granules Pharmaceuticals Inc Step down subsidiary Purchase of goods or services Approved 4560000 0 0
66 Granules Consumer Health Inc Granules Pharmaceuticals Inc Step down subsidiary Loan Approved 1381790000 0 0
67 Granules Consumer Health Inc Granules Pharmaceuticals Inc Step down subsidiary Any other transaction Loan repaid Approved 190360000 0 0
68 Granules Consumer Health Inc Granules Pharmaceuticals Inc Step down subsidiary Any other transaction Recovery of expenses Approved 1440000 0 0
69 Granules Consumer Health Inc Granules Pharmaceuticals Inc Step down subsidiary Any other transaction Reimbursement of Expenses Approved 10380000 0 0
70 Granules Consumer Health Inc Granules Life Sciences Pvt Ltd Subsidiary Purchase of goods or services 620500000 Approved 593650000 0 0
71 Granules Consumer Health Inc Product Armor Packaging Pvt Ltd Enterprises over which key management personnel or their relatives exercise significant influence Purchase of goods or services Approved 35210000 0 0
72 Granules Consumer Health Inc Granules Pharmaceuticals Inc Step down subsidiary Any other transaction Trade Receivable Approved 0 34670000 46310000
73 Granules Consumer Health Inc Granules Pharmaceuticals Inc Step down subsidiary Any other transaction Loan payable Approved 0 385310000 1572440000
74 Granules Consumer Health Inc Granules Pharmaceuticals Inc Step down subsidiary Any other transaction Trade Payable Approved 0 20590000 36130000
75 Granules Consumer Health Inc Granules Pharmaceuticals Inc Step down subsidiary Any other transaction Other Payable Approved 0 0 0
76 Granules Consumer Health Inc Granules Life Sciences Pvt Ltd Subsidiary Any other transaction Trade Payable Approved 0 26850000 619790000
77 Granules Consumer Health Inc Product Armor Packaging Pvt Ltd Enterprises over which key management personnel or their relatives exercise significant influence Any other transaction Trade Payable Approved 0 4230000 17550000
78 Granules Pharmaceuticals Inc Granules USA Inc Subsidiary Purchase of goods or services Approved 14860000 0 0
79 Granules Pharmaceuticals Inc Granules USA Inc Subsidiary Any other transaction Reimbursement of Expenses Approved 77040000 0 0
80 Granules Pharmaceuticals Inc Granules USA Inc Subsidiary Any other transaction Reimbursement from Expenses Approved 150000 0 0
81 Granules Pharmaceuticals Inc Mrs. Priyanka Chigurupati Key Management Personnel Any other transaction Settlement of employee stock options Approved 57040000 0 0
Total value of transaction during the reporting period 15195500000